Scancell Holdings plc (SCNLF)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 16.66 Million GBP | 18.54% |
| 2022 | 13.29 Million GBP | 50.54% |
| 2021 | 8.83 Million GBP | 30.26% |
| 2020 | 6.78 Million GBP | 0.79% |
| 2019 | 6.72 Million GBP | 36.17% |
| 2018 | 4.94 Million GBP | 8.64% |
| 2017 | 4.54 Million GBP | 49.48% |
| 2016 | 3.04 Million GBP | 2.81% |
| 2015 | 2.95 Million GBP | 18.53% |
| 2014 | 2.49 Million GBP | 14.34% |
| 2013 | 2.18 Million GBP | 11.34% |
| 2012 | 1.96 Million GBP | 121.64% |
| 2011 | 885 Thousand GBP | 23.95% |
| 2010 | 714 Thousand GBP | 232.09% |
| 2009 | 215 Thousand GBP | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.62 Million GBP | -81.86% |
| 2024 Q2 | 1.62 Million GBP | 0.0% |
| 2023 Q3 | 4.98 Million GBP | -26.59% |
| 2023 FY | 15.76 Million GBP | 18.54% |
| 2023 Q1 | 5.09 Million GBP | -35.21% |
| 2023 Q2 | 6.78 Million GBP | 33.13% |
| 2023 Q4 | 8.97 Million GBP | 80.19% |
| 2022 Q2 | 5.65 Million GBP | 168.39% |
| 2022 FY | 13.29 Million GBP | 50.54% |
| 2022 Q4 | 7.86 Million GBP | 80.63% |
| 2022 Q3 | 4.35 Million GBP | -22.96% |
| 2022 Q1 | 2.1 Million GBP | -67.88% |
| 2021 Q2 | 2.94 Million GBP | 42.31% |
| 2021 Q4 | 6.56 Million GBP | 19.05% |
| 2021 Q3 | 5.51 Million GBP | 87.24% |
| 2021 Q1 | 2.06 Million GBP | -43.44% |
| 2021 FY | 8.83 Million GBP | 30.26% |
| 2020 FY | 6.78 Million GBP | 0.79% |
| 2020 Q3 | 1.84 Million GBP | -40.12% |
| 2020 Q4 | 3.65 Million GBP | 98.07% |
| 2020 Q2 | 3.08 Million GBP | 99.52% |
| 2020 Q1 | 1.54 Million GBP | 1.24% |
| 2019 Q1 | 1.83 Million GBP | 43.92% |
| 2019 FY | 6.72 Million GBP | 36.17% |
| 2019 Q2 | 1.83 Million GBP | -0.0% |
| 2019 Q3 | 1.52 Million GBP | -16.99% |
| 2019 Q4 | 1.52 Million GBP | 0.0% |
| 2018 Q2 | 1.19 Million GBP | 0.0% |
| 2018 Q4 | 1.27 Million GBP | 0.0% |
| 2018 Q1 | 1.19 Million GBP | -2.09% |
| 2018 FY | 4.94 Million GBP | 8.64% |
| 2018 Q3 | 1.27 Million GBP | 7.03% |
| 2017 Q4 | 1.21 Million GBP | 0.0% |
| 2017 Q1 | 1.05 Million GBP | 25.99% |
| 2017 Q2 | 1.05 Million GBP | -0.0% |
| 2017 Q3 | 1.21 Million GBP | 15.5% |
| 2017 FY | 4.54 Million GBP | 49.48% |
| 2016 FY | 3.04 Million GBP | 2.81% |
| 2016 Q2 | 683.88 Thousand GBP | -0.0% |
| 2016 Q3 | 837.69 Thousand GBP | 22.49% |
| 2016 Q4 | 837.69 Thousand GBP | 0.0% |
| 2016 Q1 | 683.88 Thousand GBP | -2.24% |
| 2015 Q2 | 780.4 Thousand GBP | -0.0% |
| 2015 Q3 | 699.59 Thousand GBP | -10.36% |
| 2015 FY | 2.95 Million GBP | 18.53% |
| 2015 Q1 | 780.4 Thousand GBP | 31.09% |
| 2015 Q4 | 699.59 Thousand GBP | 0.0% |
| 2014 Q3 | 595.33 Thousand GBP | -8.87% |
| 2014 Q1 | 653.27 Thousand GBP | 9.43% |
| 2014 Q4 | 595.33 Thousand GBP | 0.0% |
| 2014 FY | 2.49 Million GBP | 14.34% |
| 2014 Q2 | 653.27 Thousand GBP | 0.0% |
| 2013 Q4 | 597 Thousand GBP | 0.0% |
| 2013 FY | 2.18 Million GBP | 11.34% |
| 2013 Q3 | 597 Thousand GBP | 0.0% |
| 2012 FY | 1.96 Million GBP | 121.64% |
| 2011 FY | 885 Thousand GBP | 23.95% |
| 2010 FY | 714 Thousand GBP | 232.09% |
| 2009 FY | 215 Thousand GBP | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 80.796% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -238.884% |
| SQZ Biotechnologies Company | 85.61 Million USD | 80.535% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 43.606% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 55.266% |
| Mesoblast Limited | 5.9 Million USD | -182.379% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1009.662% |
| Genus plc | 147.7 Million USD | 88.716% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -89.834% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1142.299% |
| Marizyme, Inc. | 19.23 Million USD | 13.378% |
| ContraFect Corporation | 56.88 Million USD | 70.704% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -99.856% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -278.028% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1027.031% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -471.49% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -497.271% |
| MultiCell Technologies, Inc. | 567.42 USD | -2937054.136% |
| Accustem Sciences Inc. | 3.74 Million USD | -344.851% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 80.609% |
| EV Biologics, Inc. | 531.96 Thousand USD | -3032.931% |
| Q BioMed Inc. | 3.43 Million USD | -384.952% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 32.567% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -4178.094% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -534.286% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1576.353% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 92.609% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -148.079% |
| Skye Bioscience, Inc. | 13.54 Million USD | -23.019% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -713.489% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 66764.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -230.541% |
| IMV Inc. | 37.7 Million USD | 55.804% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -4.096% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -808.182% |
| GB Sciences, Inc. | 1.42 Million USD | -1073.241% |
| Alpha Cognition Inc. | 9.7 Million USD | -71.715% |
| HST Global, Inc. | 140.9 Thousand USD | -11727.659% |
| CSL Limited | 3.44 Billion USD | 99.517% |
| Halberd Corporation | 74.84 Thousand USD | -22168.245% |
| Enzolytics Inc. | 2.17 Million USD | -664.668% |
| Resverlogix Corp. | 12.71 Million USD | -31.104% |
| Affymax, Inc. | 39.38 Million USD | 57.685% |
| SYBLEU INC | 160.87 Thousand USD | -10259.532% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -356.514% |
| argenx SE | 1.53 Billion USD | 98.913% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 70.985% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1496.36% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -955.241% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -389.46% |
| AVAX Technologies, Inc. | 7.31 Million USD | -127.981% |
| Zenith Capital Corp. | 8.94 Million USD | -86.358% |
| Genscript Biotech Corporation | 825.34 Million USD | 97.981% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -95566.15% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -578.772% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -9617.274% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 83.222% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -847.105% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -745.117% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -793.921% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -53.363% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -767.611% |
| BioStem Technologies, Inc. | 22.97 Million USD | 27.46% |
| ONE Bio Corp. | 6.44 Million USD | -158.633% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -9083.128% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -1147.987% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1381.541% |
| Agentix Corp. | 1.37 Million USD | -1114.939% |
| LadRx Corporation | 3.81 Million USD | -337.222% |
| Cell Source, Inc. | 4.32 Million USD | -285.31% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -3911.274% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1704.637% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1704.637% |
| NovAccess Global Inc. | 2.46 Million USD | -575.623% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -592.992% |
| Itoco Inc. | 919.14 Thousand USD | -1713.211% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -293.213% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1389.366% |
| Kadimastem Ltd | 2.41 Million USD | -591.503% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -6267.728% |
| CytoDyn Inc. | 18.05 Million USD | 7.708% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -66116.377% |
| Mobile Lads Corp. | 554.54 Thousand USD | -2905.341% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -7472.77% |
| Qrons Inc. | 643.67 Thousand USD | -2489.187% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -1073.834% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -647.395% |
| Rebus Holdings, Inc. | 664 Thousand USD | -2409.94% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -817.57% |
| International Stem Cell Corporation | 5.27 Million USD | -216.183% |
| Bioxytran, Inc. | 3.82 Million USD | -336.266% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -31559.131% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -81824.986% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 54.045% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -930.037% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -2164.91% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -435.712% |
| Neutra Corp. | 243.82 Thousand USD | -6735.342% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 4.531% |
| PureTech Health plc | 144.59 Million USD | 88.474% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 18.662% |
| IXICO plc | 4.7 Million USD | -254.068% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -89.451% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 85.846% |
| CSL Limited | 3.89 Billion USD | 99.572% |
| Cellectis S.A. | 97.32 Million USD | 82.875% |